Dr Reddy’s Laboratories announced on today that it has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL, for subcutaneous use in the US market on February 25.
It is a therapeutic equivalent generic version of IMITREX STATdose Pen® (sumatriptan succinate) 6 mg/0.5 mL. The product got approval from the United States Food & Drug Administration (USFDA), the Hyderabad-based pharma major said in a release.
Dr Reddy’s Sumatriptan Injection USP, Autoinjector System 6 mg/ 0.5 mL is available in a carton containing 2 single-dose prefilled syringes.
The IMITREX STATdose Pen brand and generic combined had U.S. sales of approximately $169 million for the most recent twelve months ending in December 2013 according to IMS Health.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.